Incidence of cardiovascular disease-related events and all-cause hospitalisations associated with exenatide versus insulin, thiazolidinediones, sulfonylureas, metformin and sitagliptin in patients with type 2 diabetes mellitus.
Phase of Trial: Phase IV
Latest Information Update: 18 Nov 2010
At a glance
- Drugs Exenatide; Insulin; Metformin; Sitagliptin; Sulfonylureas; Thiazolidinediones
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Amylin Pharmaceuticals; Eli Lilly
- 18 Nov 2010 New trial record
- 17 Nov 2010 Results were presented at the American Heart Association 2010 Scientific Sessions, according to an Amylin Pharmaceuticals and Eli Lilly media release.